Peptide administration for lung fibrosis treatment using formulation based on medusa technology. develop a sustained release formulation os p144 or p17, loquid or freeze-dried form, for subcutaneous administration route and carry on preclinical and clinical trials.
Invitrotek ltd. Sti. (Istanbul, turkey) and pronto diagnostics ltd. (Tel aviv, israel) will collaborate in developing an assay, based on the targeted next generation sequencing to detect mutations in all thalassemia cases.
To investigate the possibility of developing biomarkers for hcc prognosis and companion diagnostics by using advanced sequencing technologies (ngs) and the data analysis algorithms for a set of target biomarkers.
The primary goal of the project evita is to develop an innovative dermatological product formulation dermavit for treatment of specific severe cutaneous side effects induced by therapy in oncology patients and to improve their quality of life.
The project aims the development of generic purification procedures to obtain endotoxin standards, the development of analytical test kits to quantify endotoxins in liquid formulations and the development of endotoxin specific filter materials to purify liquid formulations from endotoxins.
Therabodc aims at discovery of specific antibody fragments targeting g protein coupled receptors up regulated in tumor cells. The 2nd step is conjugating several anti-cancer drugs to the discovered antibody fragments. The 3rd is validating efficacy of combined molecules in cellular and animal model.